Jinze Li
李金泽
Jinze Li (李金泽, Dr. Robert Li) is the founder and CEO of Ze'an Biopharmaceutical (泽安生物 / LTZ), a biotech company developing a myeloid cell engager pipeline. In that capacity he led the company through a $40 million Series A+ round in April 2025 and a partnership with GSK carrying a $50 million upfront payment, announced in November 2025, where he was quoted on GSK's oncology heritage and global reach . As of a May 2026 portfolio update, he remained founder-CEO, framing a new financing round as the company's move "from technology platform validation to clinical value realization" . Beyond his role at LTZ, elsewhere's corpus does not cover his background.
AI-generated — may contain errors, please verify.
Coverage
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Vol.16, May 12, 2026
Staying with you through milestone moments at Qiming Venture Partners' portfolio companies
$50 Million Upfront Payment! Zeon Secures Another Partnership with Global Pharma Giant | BlueRun Ventures Family Headlines
Ze'an Partners with Another Global Pharma Giant
Zean completes $40 million Series A+ round to accelerate development of myeloid cell engager pipeline | BlueRun Ventures Family
Focusing on unmet clinical needs in major disease areas such as cancer and autoimmune diseases.
